Results 1 to 10 of about 3,375 (120)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311) [PDF]

Frontiers in Oncology, 2023
BackgroundIntratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin and nivolumab may have synergistic effects in advanced sarcomas.Patients and ...
Erlinda M Gordon
exaly   +4 more sources

Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial [PDF]

Molecular Therapy: Oncology
Peritoneal surface malignancies (PSMs) remain a therapeutic challenge, particularly in patients with unresectable disease who cannot benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
John H. Stewart, IV, Donna Niedzwiecki, Melissa Lowe, Ashley Moyer, Emily Bolch, Shannon Diane MacLaughlan, Edward A. Levine, Omeed Moaven, Niharika Mettu, John H. Strickler, Dan G. Blazer, III   +10 more
doaj   +2 more sources

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class [PDF]

Frontiers in Molecular Biosciences, 2022
Talimogene laherparepvec (T-VEC) is a modified oncolytic herpes Simplex virus, type 1 (HSV-1) encoding granulocyte-macrophage colony stimulating factor (GM-CSF).
Howard L. Kaufman, Howard L. Kaufman, Sophia Z. Shalhout, Gail Iodice   +3 more
doaj   +2 more sources

Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report [PDF]

Journal of Medical Case Reports
Background Mucosal melanoma, an aggressive type of malignancy different from the cutaneous melanomas commonly seen in the head and neck region, represents 
Saurabh D. Chitnis, Nolan B. Seim, Kari Kendra   +2 more
doaj   +2 more sources

A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma [PDF]

Clinical Case Reports
Cytomegalovirus (CMV) reactivation is a rare complication in patients treated with immune checkpoint inhibitors (ICIs), typically occurring after immunosuppressive therapy for immune‐related adverse events (irAEs). Here, we report a unique case of severe
Goar Egoryan, Alex Zimmet, Mingwei Yu, Joseph Pozdol, Aruna Subramanian, Sunil Reddy, Joanna Nelson   +6 more
doaj   +2 more sources

Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment [PDF]

Journal for ImmunoTherapy of Cancer, 2022
Talimogene laherparepvec (T-VEC) has become an increasingly popular treatment option for surgically non-resectable, recurrent melanoma, usually of cutaneous metastases.
Jennifer Gardner, Song Y Park, Austin R Green, Rouba Hadi, Coley Doolittle-Amieva, Ata S Moshiri   +5 more
doaj   +2 more sources

Talimogene laherparepvec: First in class oncolytic virotherapy

Human Vaccines and Immunotherapeutics, 2018
Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at ...
Robert Conry
exaly   +2 more sources

Talimogene Laherparepvec treatment for mucosal melanoma with metastatic lymph node metastasis: case report [PDF]

Frontiers in Oncology
Mucosal melanoma is a rare and aggressive subtype of melanoma, accounting for approximately 1% of all melanoma cases. Of those, only 4% occur primarily in the vagina.
Arnar B. Ingason, Venkatesa P. Muruganandam, Ikechukwu Chidobem, Jessica Cintolo-Gonzalez, Hibba tul Rehman   +4 more
doaj   +2 more sources

Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma [PDF]

Journal for ImmunoTherapy of Cancer
Background Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus therapy approved for treatment of unresectable and metastatic melanoma. However, real-world use often occurs in heavily pretreated patients, where evidence of effectiveness ...
Shailender Bhatia, Paul T Nghiem, George Ansstas, Song Y Park, Coley Doolittle-Amieva, Evan T Hall, Melissa M Yamada, Smitha Chandrasekhar, Ted A Gooley, Rita E Chen, David Y Chen   +10 more
doaj   +2 more sources

Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS) [PDF]

Journal of Pharmaceutical Health Care and Sciences
Background Oncolytic virus therapy is a rapidly evolving emerging approach for the medical management of cancer. Talimogene laherparepvec (T-VEC) is the first and only Food and Drug Administration (FDA)-approved oncolytic virus therapy.
Yifan Hong, Kebin Cheng, Han Qu, Yuting Wang, Yuanyuan Wang, Guorong Fan, Zhenghua Wu   +6 more
doaj   +2 more sources